

# Session 2: Maintaining a leading position within Life Science

---

**Arrangør** ATV's temagrupper for Sundhed, forebyggelse og sundhedsteknologi

---

**Tid** 9. november 2017 14:30-16:30

---

**Sted** Mødelokale AMAGER STRAND, 1. sal, DGI-byen

---

## Innovation strategies in life science companies

Denmark currently holds a leading position within life science and medtech, and the potential for further growth within these sectors is substantial. However, the position is challenged by rapid technological development that may transform these industries. Constant innovation is a prerequisite in order to stay in top.

In this session, we will discuss how innovation takes place in different companies. Which challenges do younger companies and start-ups face, and how do they differ from the challenges that older and more established companies meet? Is there an inherent difference between the innovation strategies chosen by pharma industry as opposed to the strategy of medtech companies?

Six companies will share their approach to innovation and discuss what is needed if Denmark is to maintain a leading position within life science.



Uddannelses- og  
Forskningsministeriet

—  
Styrelsen for Institutioner  
og Uddannelsesstøtte



Innovationsnetværk for it

## Program

Moderator: Professor Poul Nissen, Institut for Molekylærbiologi og Genetik, AU

---

14:30 – **Indledende bemærkninger**  
14:40 *Professor Poul Nissen, Institut for Molekylærbiologi og Genetik, AU*

---

14:40 – **3Shape - How to cope with 30% growth ten years in a row**  
14:50 *Dr. Karl Hollenbeck, Department Head, Scanner Technology, 3Shape*

---

14:50 – **How to start-up a medtech company**  
15:00 *Jacob E. Nielsen, Co-founder, Cortrium*

---

15:00 – **How to survive as a small independent Medico startup**  
15:10 *CEO Jørgen Ole Kjær, Spiromagic*

---

15:10 – **The local talent pool & Lundbeck future success**  
15:20 *Kim Andersen, SVP, Head of Research, Lundbeck A/S*

---

15:20 – **Innovation network – a future operating model for technology companies?**  
15:30 *Thorsten Thormann, Vice President of Research, LEO Pharma*

---

15:30 – **Using virtual tools to reduce development times**  
15:40 *Søren Mikkelsen, Corporate Vice President, Sustainable Device Innovation, Novo Nordisk A/S*

---

15:40 – **Debat**  
16:25

---

16:25 – **Afsluttende bemærkninger**  
16:30 *Professor Poul Nissen, Institut for Molekylærbiologi og Genetik, AU*

---

16:30 – **Vi mødes i hovedsalen**  
16:45

---

## About the speakers

### **Karl Hollenbeck, Head of Scanner Technology at 3Shape A/S**

Scanner Technology works on evaluation and initial prototyping of new technologies with relevance to the company. Karl has a B.Sc. from the University of Freiburg, Germany, an M.S. from the University of Virginia, and a Ph.D. from DTU, all in Environmental Studies with specialization on numerical and statistical methods. Karl has also been visiting researcher at Stanford and Harvard Universities. Karl spent the first eight years of his professional career at DHI, most recently as Head of Innovation for a software department. He joined 3Shape in 2007 and has had various functions in the company since then, particularly as project manager of the initial development of Trios, the company's by now highly successful intraoral scanner. Karl has co-authored several 3Shape patents and two successful grant applications to Innovationsfonden, and has collaborated with various departments at KU and DTU on several projects.

### **Jacob Eric Nielsen, Co-founder and COO, Cortrium**

Jacob Eric Nielsen has a M.Sc. and is co-founder of and COO at Cortrium. His expertise is in Public-Private Partnerships (PPP), Entrepreneurship, Telemedicine, Fundraising, and Digital Healthcare.

### **Jørgen Ole Kjær, CEO, Spiromagic**

Jørgen Ole Kjær is a civil engineer from DTU. Jørgen Ole Kjær works with leadership and innovation and is CEO in Spiromagic and Move Innovation. He is president of the company Mouldflo A/S. Spiromagic is being approved in November/December 2017 as a medical company and is ready for market launch in the beginning of 2018. Move Innovation is named a Gazelle in 2017 and is exporting to more than 20 countries.

### **Kim Andersen, Senior Vice President and Head of Research, Lundbeck A/S**

Kim Andersen, PhD, is Senior Vice President and Head of Research at Lundbeck. He is member of Lundbeck's R&D Executive Committee. He started his career with Lundbeck in 1989 and has held different positions within medicinal chemistry including five years as head of department in Denmark and Vice President of Medicinal Chemistry at Lundbeck Research USA, Inc. (formerly Synaptic Pharmaceuticals). In 2006 he returned to the headquarters in Denmark and took on the position as Director of Research Operations and Project Portfolio Management Research, a position he held until becoming Vice President of the Danish research site in 2008. Kim Andersen holds a MSc in Chemical Engineering and a PhD from the Danish School of Pharmacy, Copenhagen.

### **Søren Mikkelsen**

Søren Mikkelsen has contributed to the medical device industry through his 30 years' career within device innovation. Currently Søren is driving medical device innovation in Novo Nordisk A/S - from concept stage to high scale production and market entry. Søren has through his career been driving device development within

therapeutic areas such as; central nervous system, growth hormone treatment, diabetes and other related chronic diseases. Søren is holding a degree in Mechanical Engineering.

**Thorsten Thormann, Vice President, Research, Leo Pharma A/S**

Thorsten Thormann is Vice President of Research in LEO Pharma, a function that builds and maintains a strong R&D project pipeline. Thorsten has over 15 years of experience within biomedicine and drug research and he and his team has over the past years brought a number of molecules into clinical testing. This has resulted in two marketed products and a handful of programs currently in clinical development. Prior to being Vice President of Research, Thorsten has over the years held a number of leadership positions within LEO Pharma aiming to build translational drug discovery platforms in dermatology as well as refocusing the early formulation and CMC to build a platform for product improvements based on usability and patient driven innovation. Thorsten Thormann has a MSc in Chemistry from University of Roskilde and a PhD in Protein Biology from University of Copenhagen